cell signaling, one of key processes in both normal cellular function and disease, is coordinated by numerous interactions between membrane proteins that change in response to stimuli. We present a split ubiquitin-based method for detection of integral membrane protein-protein interactions (PPis) in human cells, termed mammalian-membrane two-hybrid assay (mamth). We show that this technology detects stimulus (hormone or agonist)-dependent and phosphorylationdependent PPis. mamth can detect changes in PPis conferred by mutations such as those in oncogenic erbB receptor variants or by treatment with drugs such as the tyrosine kinase inhibitor erlotinib. using mamth as a screening assay, we identified crKii as an interactor of oncogenic eGFr(l858r) and showed that crKii promotes persistent activation of aberrant signaling in non-small cell lung cancer cells. mamth is a powerful tool for investigating the dynamic interactomes of human integral membrane proteins.
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Membrane proteins, which comprise nearly 30% of the proteome 1 , have pivotal roles in cellular processes and are major targets for the development of new therapeutics. Understanding membraneprotein function depends on studies of physical interactions of these proteins within complexes. However, it is a major challenge to investigate the complex protein networks of integral membrane proteins both under normal and disease-related conditions.
In cancer, signaling pathways often have variations in phosphorylation patterns of signaling components, which leads to increased association with downstream adaptors and subsequently to proliferation of malignant cells. Thus, mammalian cell-based assays that identify changes in PPIs conferred by aberrant signaling pathways can help understand disease mechanisms and define new drug targets. For example, signaling via the ErbB family of receptor tyrosine kinases is implicated in cancer progression and has been well analyzed by classical biochemical methods 2, 3 . Mass spectrometry (MS)-based biochemical assays are often unsuitable for detecting transient and modification-dependent PPIs. A range of methods has emerged to uncover PPIs in mammalian cells as a function of physiological context: for instance, genetic systems such as protein fragment complementation assays have been applied to map membrane PPIs [4] [5] [6] [7] . Protein fragment complementation assays and their variants have also been applied to detect ligand-dependent interactions of ErbB family receptors and ligand-induced G protein-coupled receptor (GPCR) activation 8, 9 as well as hormone-induced ErbB heterodimerization 10 . Finally, techniques such as fluorescence and bioluminescence resonance energy transfter 11 or mammalian protein-protein interaction trap 4 are valuable tools to study signaling pathways but are technically challenging or are not suitable for mapping integral-membrane PPIs. There remains a lack of mammalian cell-based highthroughput assays to detect interaction patterns of membrane proteins in response to drugs, natural stimuli or ligands.
Here we present a split-ubiquitin two-hybrid approach, called MaMTH, to study PPIs of full-length integral membrane proteins in stimuli-dependent contexts in mammalian cells. We applied MaMTH to study the interactions of wild-type and oncogenic variants of ErbB receptor tyrosine kinase family members under varying conditions, in a targeted screen and identified CRKII as an interactor of oncogenic epidermal growth factor receptor (EGFR).
results development of mamth
MaMTH is based on the split-ubiquitin assay 12 and is derived from the membrane yeast two-hybrid (MYTH) assay [13] [14] [15] . A membrane bait protein is tagged with the C-terminal half of ubiquitin (Cub) and a chimeric transcription factor (TF), and a cytosolic or membrane-bound prey is tagged with the N-terminal half of ubiquitin (Nub). Upon interaction of bait and prey, the split halves form pseudoubiquitin, which is recognized by cytosolic deubiquitinating enzymes, resulting in cleavage of the TF and expression of a reporter gene (Fig. 1a) . We determined conditions permitting us to adapt MYTH to mammalian cells (Supplementary Fig. 1 ). First, we tested suitable TFs [16] [17] [18] for reporter-gene activation in HEK293T cells stably expressing reporter constructs either containing eight lexA operator repeats followed by the luciferase gene (8×lexAops-luciferase) or five GAL4 upstream activating sequence repeats followed by the luciferase gene (5×GAL4UAS-luciferase). We found that the TFs comprising amino acids 1-147 of GAL4 fused to amino acids 364-550 of mouse NF-κB (GAL4(1-147)-mNF-κB(364-550)) and mutated LexA fused to VP16 (mLexA(1-202)-VP16(413-490)) resulted in the highest luciferase induction. Next, we tested various linkers 7, 13, 19 between the bait or prey cDNAs and the sequences encoding ubiquitin halves and found that glycine-serine linkers allowed for the most efficient ubiquitin reconstitution. We also tested Nub variants and determined that human wild-type 'NubI' and Cub displayed the best affinity, which differs from the yeast system that requires the use of mutant 'NubG' with reduced Cub affinity 12, 20 . Finally, we incorporated sequence encoding a LexA variant lacking a nuclear localization signal-like sequence (mLexA 21 ), into the bait constructs, which reduced background activation. We show the final arrangement of all constructs in Supplementary Figure 1e .
mamth performance and validation
We applied the MaMTH assay to study known interactions of the ErbB4 and EGF receptors. We infected 5×GAL4UAS-luciferase, 5×GAL4UAS-GFP, 8×lexAops-luciferase and 8×lexAops-GFP HEK293T reporter cells stably expressing ErbB4-Cub-TF with Nub-Shc1 or Nub-Grb2 preys (positive controls) or Nub-Fabp5 (negative control) and measured reporter activation (GFP or luciferase; Fig. 1b and Supplementary Fig. 2 ). MaMTH assay detected PPIs between ErbB4-Cub-TF and positive controls in all TF setups we tested. Reporter-gene activation correlated with TF npg cleavage, as monitored by western blot. Either GFP or luciferase reporters can be used in MaMTH, but because the luciferase setup is faster and more scaleable, we performed subsequent experiments using luciferase reporters. The ErbB-Cub-GFP-TF fusions properly localized to the plasma membrane, which demonstrated that tagging does not affect proper localization (Supplementary Fig. 3a) . To ensure that NubI does not lead to nonspecific interactions, we reconstituted known PPIs and observed comparable results for all bait proteins tested. We tested ErbB baits with a panel of preys that contained 16 negativecontrol preys and known interactors such as Shc1, Grb2 and Hsp90, which were all well detected above negative controls ( Fig. 1c and Supplementary Fig. 3b-f ). Cfl1 and GAPDH, which previously had been shown to interact with EGFR 22 , also interacted with ErbB4-Cub-TF in our assay. We reconstituted the interaction between GPCR heterodimers GABBR1 and GABBR2, and the interaction between the ABC transporters ABCD1 and ABCD2 among panels of 14 and 6 negative-control preys, respectively ( Supplementary Fig. 3e,f) . Transient expression as well as stable expression of bait and prey proteins showed comparable results ( Supplementary Fig. 4 ).
mamth detects agonist-induced interactions
We reconstituted the PPI between human β2-adrenergic receptor (β2-AR) and β-arrestin. β-arrestin associates with β2-AR once an agonist such as isoproterenol binds the receptor, leading to G-protein signaling and GRK-induced phosphorylation 23 . MaMTH readily detected agonist-dependent β2-AR interaction with β-arrestin (Fig. 2a) . To test whether this interaction is specific, we mutated GRK phosphorylation sites on β2-AR-Cub-mLexA-VP16. Mutant β2-AR baits were expressed at similar levels and mutant β2-AR-Cub-GFP-mLexA-VP16-baits localized properly (Fig. 2b,c and Supplementary Fig. 5 ). Mutating GRK6 or GRK2 phosphorylation sites on the receptor led to decreased β-arrestin binding upon treatment with agonist, whereas a combination of GRK6 and GRK2 mutations abolished agonist-induced β-arrestin binding (Fig. 2c) . In contrast, binding of the β2-AR to Nub-β-arrestin(R169E), which can bind nonphosphorylated β2-AR 24 , was comparable to binding to the wild-type receptor (Fig. 2d) . We note that in this case, TF cleavage did not directly correlate with luciferase activity; owing to the nature of the reporter system, it is likely that even small differences in amounts of free TF can lead to detectable differences in luciferase expression. Cells expressing unrelated protein interaction pairs (EGFR-Shc1 and ErbB2-Grb2) were unaffected by agonist treatment (Supplementary Fig. 6a ), excluding nonspecific agonist effects.
mamth maps phosphotyrosines involved in PPis
ErbB family members contain 89 tyrosine residues on their cytosolic terminus 3 , some of which are involved in stimulus-dependent A fraction of the lysates was analyzed by western blot (right). (d) Luciferase activity of HEK293T cells stably expressing the 8×lexAops-luciferasereporter and co-transfected with β2-AR-Wt-and mutant β2-AR constructs lacking GRK2 and GRK6 phosphorylation sites and Nub-β-arrestin or Nub-β-arrestin(R169E) prey constructs and treated with agonist. A fraction of the lysates was subjected to western blot analysis (right). Relative luciferase activity is based on fold-change increase above the bait-only control. Error bars (a,c,d), s.d. (n = 3 biological replicates). ***P < 0.001, **P < 0.01; two-tailed unpaired t-test compared to corresponding controls. npg interactions with adaptor proteins such as Grb2. We used MaMTH to map phosphorylation sites on ErbB receptors responsible for Grb2 binding, which yielded results consistent with previous reports 3 , and observed an additive decrease in Nub-Grb2 binding upon introduction of single (EGFR(Y1092A)) and double (EGFR(Y1092A,Y1138A)) substitutions, whereas Nub-GAPDH binding was unaffected (Fig. 3a) . Another SH2 domain-containing prey protein, Nub-CRKII, showed a binding pattern similar to that of NubGrb2. Furthermore, ErbB2(Y1139A)-Cub-GAL4-NF-κB and ErbB3(Y1262A,Y1199A)-Cub-GAL4-NF-κB baits harboring substitutions in known Grb2 phosphotyrosine binding sites showed significantly reduced binding to Nub-Grb2 upon ligand binding compared to the wild type (Fig. 3b) . Consistent with previous results 3 , we observed no effect on Nub-Shc1 binding in the Grb2 phosphorylation site variant bait ErbB2(Y1139A)-Cub-GAL4-NF-κB but detected an effect in ErbB3(Y1262A,Y1199A)-Cub-GAL4-NF-κB bait (Fig. 3b) . All ErbB baits and tested preys were expressed at comparable levels ( Fig. 3a,b) .
monitoring phosphorylation-dependent interactions
Receptor tyrosine kinase signaling cascades are mediated by numerous phosphorylation-dependent PPIs 25 . MaMTH could detect serum-dependent PPIs in cells coexpressing ErbB2-Cub-GAL4-mNF-κB and Nub-Grb2, Nub-Shc1 or Nub-Hsp90, which showed increased luciferase activity compared to cells grown in the absence of serum, indicative of activated ErbB2. This was even more pronounced when we transfected cells directly in starvation medium. Treatment with a nonspecific tyrosine kinase inhibitor (TKI-PD158780) reduced phosphorylation of ErbB4, which resulted in lower Nub-Shc1 binding (Supplementary Fig. 7) .
We then used MaMTH to monitor interactions of oncogenic ErbB variants that display constitutive kinase activity. We introduced oncogenic ErbB4 mutations 26 into ErbB4-Cub-GAL4-NF-κB baits and tested them for Nub-Shc1 binding (Fig. 4a) . We detected a significant increase in Nub-Shc1 recruitment in ErbB4(E542K)-Cub-GAL4-NF-κB and ErbB4(E872K)-Cub-GAL4-NF-κB baits (but not ErbB4(R544W)-Cub-GAL4-NF-κB) compared to wild type in the absence of serum, which correlated with their oncogenic nature. Moreover, two oncogenic variants, EGFR(G719S)-Cub-GAL4-NF-κB and EGFR(L858R)-Cub-GAL4-NF-κB 27 , also showed increased Nub-Shc1 binding in serum-free conditions (Fig. 4b) . Although EGFR(L858R)-Cub-GAL4-NF-κB displayed significantly higher Nub-Shc1 binding in serum-dependent and serum-independent conditions, the kinase-dead EGFR(D855A)-Cub-GAL4-NF-κB did not bind Nub-Shc1, which correlated with receptor phosphorylation patterns (Fig. 4c) . All ErbB baits and tested preys showed comparable expression levels ( Fig. 4a-c) . Taken together, MaMTH can be used to monitor PPIs that are dependent on the activity and phosphorylation state of a given receptor.
mamth detects drug-inhibited interactions of oncogenic eGFr
We investigated EGFR(L858R) and EGFR exon 19 deletion (EGFR-ex19del), common oncogenic EGFR variants found in non-small cell lung cancer (NSCLC) 27, 28 . Lung cancer patients carrying these variants are usually responsive to treatment with the tyrosine kinase inhibitor erlotinib (Tarceva) 27 . We applied MaMTH to detect drug-inhibited PPIs through monitoring Shc1 recruitment to EGFR variants in the presence and absence of erlotinib. MaMTH efficiently detected erlotinibmediated inhibition of EGFR(L858R)-Cub-GAL4-NF-κB and EGFR-ex19del-Cub-GAL4-NF-κB interaction with NubShc1, whereas erlotinib did not inhibit interaction of EGFRCub-GAL4-NF-κB with Nub-Shc1 (Supplementary Fig. 8a ). for (n = 3 biological replicates). ***P < 0.001, **P < 0.01, *P < 0.05; two-tailed unpaired t-test compared to corresponding controls.
showed decreased Nub-Shc1 binding at much lower erlotinib concentrations compared to EGFR(L858R)-Cub-GAL4-NF-κB, consistent with a previous report 29 .
Patients with NSCLC who are treated with erlotinib frequently develop a second EGFR substitution, T790M, which renders the receptor unresponsive to erlotinib 28 . In MaMTH, this EGFR(L858R/T790M)-bait variant indeed behaved like the wild-type receptor-bait, showing no decrease in Nub-Shc1 binding upon treatment with erlotinib (Fig. 4d) . Mutant EGFR receptor baits were expressed at levels comparable to that of wild-type EGFR, displayed correct PM localization with and without erlotinib, and showed higher basal Nub-Shc1 binding than the wild-type receptor (Supplementary Fig. 8c,e  and Fig. 4d ). Nub-Shc1 binding patterns of mutant receptor baits correlated with TF cleavage levels and EGFR phosphorylation pattern (Fig. 4d) . To rule out a nonspecific effect of erlotinib on Shc1 binding, we tested the effects of erlotinib and imatinib (a tyrosine kinase inhibitor that specifically targets Bcr-Abl 30 ) on other phosphorylation-dependent and phosphorylation-independent EGFR interactors. Whereas all four phosphorylation-dependent interactor preys showed a bait-binding pattern similar to that of Nub-Shc1 upon treatment with erlotinib, the two phosphorylationindependent interactors bound all EGFR mutant baits independent of drug treatment (Supplementary Fig. 9 ). Imatinib did not affect any interaction. Erlotinib did not influence interactions of unrelated protein-interaction pairs (Supplementary Fig. 6b ). We next tested the binding of Nub-Grb2(R86M) and NubShc1(R175Q) mutant preys, which cannot bind EGFR 31, 32 , and, as expected, observed reduced interaction with EGFR (Fig. 4e) . All EGFR baits and tested preys showed comparable expression levels (Fig. 4d,e) .
As expected, the EGFR baits in our assay can be activated by EGF (Supplementary Fig. 10 ). EGFR-Cub-GAL4-NF-κB showed Cub-GAL4-NF-κB baits: Tables 3 and 4) . 67 of these bound more strongly to EGFR(L858R), 30 bound more strongly to wildtype EGFR and 27 showed comparable binding. We determined MaMTH binding strength by comparing whether luciferase activity from bait-prey interactions was significantly higher than that from the same baits paired with negative-control preys (Online Methods). Then, we calculated the ratio between the binding pattern of wild-type EGFR and EGFR(L858R) for each bait-prey pair to depict changes in interaction patterns (Supplementary Table 4) . We detected 64.2% of known EGFR interactors (70 of 109) and identified 54 previously uncharacterized putative EGFR interactors (Supplementary Table 4 ). Most of the 39 known interactors our screen did not detect had been previously identified by co-immunoprecipitation (co-IP)-based studies (Supplementary Table 5 ). Among the 124 MaMTH-detected interactors, 13 are known prognostic markers for lung cancer (Supplementary Table 4 and Supplementary Fig. 11 ), 9 of which showed higher binding to the oncogenic mutant EGFR(L858R), which indicated that the mutant receptor preferentially binds proteins involved in aberrant signaling. We summarize the interactors found in this targeted MaMTH screen in Supplementary Figure 12 . (n = 3 biological replicates). ***P < 0.001, **P < 0.01, *P < 0.05; two-tailed unpaired t-test compared to corresponding controls. npg
Validation of eGFr interactors
As a secondary validation, we tested a subset of PPIs from our dataset using luminescence-based mammalian interactome (LUMIER) assay 33, 34 . We selected 60 interactors based on whether they showed significantly (as determined by two-tailed unpaired t-test with a P-value cutoff < 0. 35 and grew the cells with or without erlotinib. We compared shRNA abundance and calculated a relative dropout rate, which indicates whether knockdown confers a fitness disadvantage (depleted genes) or advantage (enriched genes) upon treatment with erlotinib. shRNA-mediated knockdown of CRKII, a member of the CRK family of adaptor proteins, led to a drastic fitness defect in erlotinib-treated cells, which was reflected in the greatest negative dropout rate among the 60 candidates ( Fig. 5a and Supplementary Table 7) . CRKII also interacted strongly with the oncogenic EGFR(L858R) in both MaMTH and the LUMIER assay (Fig. 5a) . These data suggest a role of CRKII in cell survival or oncogenic signaling. CRKII and CRKL, which belong to the CRK family of adaptor proteins, are often found overexpressed in various cancers 36 . We manipulated CRKII levels by knockdown or overexpression, in HCC827 cells (Fig. 5b,c) . Cells ovexpressing CRKII resulted in persistent phospho-ERK and phospho-AKT signaling in the presence of erlotinib, similar to the effect of overexpressed CRKL reported previously 37 , whereas mock-infected cells showed reduced phosphorylation upon treatment with erlotinib, as expected (Fig. 5b) . Moreover, we observed increased EGFR levels in HCC827 cells overexpressing CRKII but the opposite effect in H226 NSCLC cells expressing EGFR (Supplementary Fig. 15a,b) . CRKII overexpression improved viability of HCC827 cells in the presence of erlotinib, whereas shRNA-mediated knockdown of CRKII led to increased sensitivity to erlotinib (Fig. 5d) . We performed the same experiments with Muc1 and PDGFRA, which were also identified as EGFR interactors in the MaMTH screen, but observed no changes in phospho-ERK levels or cell viability (Supplementary Fig. 15c) . Thus, an EGFR interactor identified by MaMTH, CRKII, induced oncogenic signaling upon overexpression and can partially bypass erlotinib-mediated sensitivity in HCC827 cells. discussion Key features of MaMTH include high transferability, which allows it to be carried out in virtually any cell line, compatibility with Gateway cloning technology, capability to detect subtle changes in interaction patterns in response to various stimuli and amenability to high-throughput screening.
MaMTH can be used to map phosphorylated residues on receptor tyrosine kinases that mediate PPIs with adaptor proteins. Phosphorylated docking sites of ErbB receptors have so far only been detectable using MS-based methods 3 , but MaMTH is a cell-based platform to identify phosphorylation sites on integral membrane receptors mediating binding with effector proteins. MaMTH also allows monitoring of dynamic PPIs: it could be used to identify the increased phosphorylation state of various oncogenic ErbB family members via measurement of adaptor-protein recruitment. Finally, we detected increased protein recruitment to the erlotinib-resistant EGFR(L858R,T790M) 38 , which could in the future be used to identify new pharmaceuticals directed toward acquired tyrosine kinase inhibitor resistance 38 .
In a first approach to scale up MaMTH for high-throughput applications, we performed a targeted screen to identify changes in PPIs of wild-type EGFR and oncogenic EGFR(L858R) variant. MaMTH robustly detected 64.2% of previously identified EGFR interactors. Compared to a recent MS-based study to generate a dynamic map of wild-type and oncogenic EGFR variants 39 , our approach is more likely to capture transient and weak interactions that vary slightly between wild type and mutant. We identified 54 previously unknown EGFR interactors, and validated 11 of 23 of these by two different orthogonal methods. We additionally characterized CRKII as a new player in oncogenic EGFR signaling.
In summary, we present MaMTH as a technology to map interactions of human integral membrane proteins under desired stimulus or treatment conditions in mammalian cells. As MaMTH is performed in a multi-well format, it is easily scalable and should be adaptable to test for small-molecule compounds that interfere with PPIs involved in cell signaling. We predict that MaMTH will help expand existing large-scale PPI analyses into multiple dimensions, to probe interactome changes in response to drugs, hormones or different growth conditions. Ultimately, it should be a valuable tool in the identification of factors associated with aberrant signaling cascades and aid greatly in the development of new drug therapies to treat diseases associated with membraneprotein dysfunction. online methods Bait, prey and reporter plasmid construction. Plasmid backbones used in this study are listed in Supplementary Table 8 . Primers used to generate reporters, baits and preys are listed incells) in case of infection with preys, overexpression constructs or shRNAs for at least 48 h and expanded or frozen down for further assays. In case of infection with reporter constructs, cells were selected with hygromycin (100 µg/ml for HEK293T) for at least 7-10 d, and single cells were isolated by limited dilution. Briefly, stable reporter cells were seeded into 96-well plates that on average each well contained one cell. About 7 d later, colonies were expanded and assayed for reporter gene activation. Clones that gave high luciferase signal upon transfection with full-length TFs compared to negative controls were expanded and used for further experiments. Double bait-reporter double stable cell lines were generated through transfection, as bait lentiviral constructs exceeded the lentiviral packaging limit and gave low virus titer. To this end, MaMTH baits were cotransfected with a linear puromarker (Clontech) at a ratio 20:1 and selected in puromycin (2 µg/ml) 48 h after transfection for ~7 d. Single colonies were isolated using sterile cylinders and tested for bait expression by western blot.
Cell culture. HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS and 1% antibiotics (penicillin and streptomycin; 100× penicillin-streptomycin solution; final added concentrations 100 U/ml penicillin and 100 µg/ml streptomycin). Lung cancer cell lines HCC827 and H226 were maintained in RPMI-1640 supplemented with 10% FBS and antibiotics. Starvation conditions were performed in DMEM or RPMI without FBS or with 0.1% FBS. Erlotinib (gift of M.-S. Tsao) and imatinib (gift of members of B. Neel's laboratory) were added at indicated concentrations, agonist isoproterenol (Sigma-Aldrich) was added at a concentration of 10 µM, TKI-PD158780 (Sigma-Aldrich) was added at 2 µM, Neuregulin (Cell Signaling Technology) was added at 5-10 nM.
Cell viability assay. HCC827 cells were seeded into white 96-well plates at 6,000 cells/well. 24 h later, medium was replaced with indicated concentrations of erlotinib, and 48 h later, alamar blue (Invitrogen) was added to the media (10 µl/well). After 3-4 h, absorbance was measured at 570 nm and 600 nm and cell viability calculated relative to untreated control wells.
Transfection experiments. Transfection experiments were performed using a modified calcium phosphate method. Briefly, for a 12-well plate, 65 µl ddH 2 O and 75 µl 2× BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) were added to the DNA and 7,5 µl 2.5M CaCl 2 was then added and the tubes vortexed and incubated at room temperature for 15 min and added dropwise to the cells. 8-16 h later, the transfection mix was removed and replaced with indicated media.
MaMTH luciferase interaction assays. Firefly luciferase activity was measured as follows: infected or transfected reporter cells were lysed between 20 h (for drug treatments) or 48 h after transfection (expression analysis) or 4 d after infection. Wells were washed with PBS and Promega reporter lysis buffer (1×) plus protease inhibitor (Complete EDTA; Roche) was added. Plates were frozen at −80 °C to ensure complete lysis. Luciferase activity was measured from at least three independent experiments. Cell lysates were then measured on an injectable Berthold luminometer suitable for 96-well plates. Luciferase experiments were performed at least in triplicates, and significance was based on P values after two-tailed unpaired t-test calculations compared to corresponding controls.
For the EGFR-interaction screen, sequences encoding 205 top-predicted EGFR interactors were cloned into lentiviral prey backbones. After lentivirus generation, target cells (stable 5×GAL4UAS-luciferase reporter-HEK293T cells) were infected with prey viruses in triplicates (C-or N-terminally tagged, depending on their cellular localization) at a multiplicity of infection of ~0.3-0.4 to ensure single-copy integration per cell. Cells were selected in puromycin for at least 48 h, cell counts were performed and equal amounts of cells were transfected with wild-type EGFR or EGFR(L858R) baits in triplicate. 24 h after transfection, cells were lysed, and cell counts and luciferase assays performed. Note that bait vectors had to be transfected owing to increased cell death upon stable integration of EGFR(L858R)-Cub-GAL4-NFkB into reporter cells. Background luminescence was defined by a set negative control preys for each round of experiments. Negative controls were chosen from literature such that the proteins have previously not been reported to interact with the baits (Nub-Fabp5, Nub-Pex7, ABCD2-Nub, Nub-Pex19, GABBR2-Nub, Nub-KCTD6, Nub-FKBP12 and Clcn5-Nub). Mann-Whitney U tests were used to assess whether luciferase activity from bait-prey interactions was significantly higher than from the same baits paired with negative control preys. Each test compared 3 luciferase activity measurements from a bait-prey pair (3 replicate experiments) against 24 measurements from the same bait and 8 negative controls (3 replicate experiments for each control). Positive MaMTH interactors were then retested with GABBR1 as an unrelated bait protein to exclude spurious preys. The MaMTH interaction ratios depict the ratios of interactor versus averaged negative controls. The ratio between wild-type EGFR and EGFR(L858R) was then calculated for each bait-prey pair to depict changes in interaction patterns between wild-type EGFR and EGFR(L858R). Supplementary Table 3 provides luciferase data for the EGFR screen and the unrelated bait interaction data.
Antibodies and western blot analysis. Western blot analysis was performed using standard protocols. Briefly, cells were directly harvested in 2× sample buffer plus β-mercaptoethanol (2× SB) or harvested in 1× reporter lysis buffer (Promega) containing protease inhibitors (Complete, EDTA-free, Roche) and 2× SB was added after freezing the cells at −80 °C. For phosphorylationspecific antibodies, cells were lysed in Ripa buffer containing Na-orthovanadate, PMSF and protease inhibitor and 2× SB was added and samples were immediately boiled at 95 °C for 5 min and proceeded to western blot analysis. 5-10% of the lysates were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. Transferred samples were immunoblotted with primary antibodies, followed by incubation with HRPcoupled secondary antibodies, and detection was performed using GE Healthcare enhanced luminescence. Antibodies and dilutions are listed in Supplementary Table 10. Fluorescence microscopy. Bait constructs (harboring Cub-GFP-mLexA-VP16) were transfected into stable 8×lexAops-luciferase cells seeded on poly(l-lysine)-coated glass slips. 48 h after transfection, fluorescence microscopy was performed. Cells were washed with warm PBS and covered in 5 µg/ml Invitrogen npg CellMask Deep Red dye for 5 min at 37 °C. Cells were washed 3 times with warm PBS and immediately used for microscopy. Cells were examined using a Leica DMI 6000 B microscope with GFP and Texas Red. Images were analyzed using the Volocity software.
RNA extraction and quantitative PCR for knockdown confirmation. RNA was prepared using the RNeasy minikit (Qiagen). QuantiTect Reverse Transcription kit (Qiagen) was used to eliminate genomic DNA and synthesize cDNA from up to 1 mg of RNA. qPCR reactions were performed on a Roche LightCycler 400 using a DyNAmo Flash SYBR GreenqPCR kit (Thermo Scientific). Primer annealing was 35 s at 50 °C and extension was 35 seconds at 72 °C (ref. 42 ).
LUMIER assay. HEK293T cells were transfected in 96-well plates with EGFR-Renilla or EGFR(L858R)-Renilla luciferase fusion constructs together with 60 selected 3xFlag-tagged bait plasmids. One day after transfection, normal growth medium (DMEM with 10% FBS) was replaced by low serum medium (DMEM with 0.1% FBS) for 16 h. Cells were treated with 100 ng/ml EGF or left untreated for 15 min before cell lysis. LUMIER assay was performed as described previously 34 , except that interactions were not normalized to the bait protein abundance. LUMIER assay was performed in duplicates in three independent rounds. Interactors were deemed significant based on P values after t-test calculations compared to corresponding backgrounds. EGFR predictions. EGFR interactors were computationally predicted using a data-mining based method, FpClass, which integrates diverse PPI evidence, including features that comprehensively characterize individual proteins and protein pairs. Features of individual proteins comprise domains, posttranslational modifications, physicochemical properties, localization, function and process. The probability of interaction depends on pairs of these features possessed by candidate interacting proteins; for example, interaction probability increases if proteins possess complementary domains that can facilitate binding. A pair of features increases (decreases) the probability of interaction if it is significantly enriched (deficient) among experimentally validated physical PPIs from the Interologous Interaction Database ver. 2.0 (I2D; http://ophid.utoronto.ca/i2d) 43 . The following features of protein pairs are also used as evidence for interaction: high co-expression of the genes encoding the protein pair, known interactions of orthologous or paralogous protein pairs, and shared interaction partners in a network of experimentally validated PPIs from I2D. Evidence from all features is integrated into a single probability of interaction. The method is fully described and tested elsewhere (Kotlyar, M., Pastrello, C., Lo Sardo, A., Niu, Y., Ding, Z., Vafaee, F., Broackes-Carter, F., Mills, G.B., Maestro, R., & Jurisica, I. Systematically characterizing human proteins without reported interactions; unpublished data). Lung prognostic signatures were downloaded from the Lung Cancer Data Integration Portal (LCDIP) database (data not shown), which includes signatures from ref. 44 and other sources.
Validation of novel EGFR interactions by co-immunoprecipitation and immunoblotting. HEK293T cells were seeded at 5 × 10 5 cells/well in a 6-well dish in DMEM with 10% FBS. The following day, cells were cotransfected with plasmids encoding Flag-tagged candidate EGFR interactors and GFP-tagged EGFR. 24-h posttransfection, cells were stimulated with EGF (100 ng/ml) for 5 min, washed twice with ice-cold PBS, and lysed in 500 µl NP40 lysis buffer (50 mM HEPES-NaOH (pH 8), 150 mM NaCl, 1 mM EGTA, 0.5% NP40, 100 mM NaF, 2.5 mM MgCl 2 , 10 mM Na 4 P 2 O 7 , 1 mM dithiothreitol (DTT) and 10% glycerol) supplemented with protease and phosphatase inhibitors (50 mM β-glycerolphosphate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM Na 3 VO 4 , 100 nM calyculin A, 1 mM PMSF). The total cell lysates were centrifuged at 20,800g for 30 min to pellet the nuclei and insoluble material. Nuclear-free lysates were precleared by one-hour incubation with protein A sepharose and normalized for total protein concentration using the Bio-Rad protein assay. Flag-tagged candidate proteins were immunoprecipitated by incubating lysates with 5 µl (bed volume) anti-Flag M2 antibody-conjugated agarose for 4 h at 4 °C. The beads were washed 4 times with lysis buffer. Co-immunoprecipitating proteins were resolved on 10% SDS-PAGE. Levels of GFP-EGFR were detected by immunoblotting using anti-GFP antibodies.
Validation of new EGFR interactions by co-immunoprecipitation and mass spectrometry. 5 × 10 6 HEK293T cells were cotransfected in a 10 cm tissue culture dish with sequences encoding Flag-tagged candidate EGFR interactors and GFP-tagged EGFR for 24 h. GFP-tagged EGFR was affinity purified using GFP Trap coupled to agarose (ChromoTek). The beads were washed 4 times with lysis buffer and twice with 50 mM ABC before resuspending in 20 µl ABC (50 mM). Tryptic digestion was performed by directly adding trypsin (enzyme:substrate ratio, ~1:50) to the beads and incubating at 37 °C overnight. The digestion was stopped by adding 3% formic acid to the reaction and the supernatant was transferred into a clean tube and dried.
Dried tryptic samples were reconstituted with 3% formic acid in HPLC grade water. Samples were loaded on to a 75 µm inner diameter and 360 µm outer diameter pulled tip packed with 3 µm ReproSil C18 and analyzed on an TripleTOF 5600 mass spectrometer (AB SCIEX) coupled to an Eksigent nanoLC Ultra 1D plus pump with a flow rate of 200 nl/min and a gradient of 2% to 35% acetonitrile over 90 min. The mass spectrometers were operated in information-dependent acquisition mode. A cycle time of 1.3 s was employed using a survey TOF scan of 250 ms at ~30,000 resolution followed by selection of the top 20 most intense peptides for MS/MS for 50 ms each with high sensitivity (at ~18,000 resolution). Only peptides with a charge state above +1 were selected for MS/MS and dynamic exclusion was set to 15 s for all ions within 20 p.p.m.
shRNA-knockdown screens and data analysis. Following the protocol detailed in ref. 45 , pooled shRNA screen measurements were performed at three time points (t 0 (cells without erlotinib treatment), t 1 and t 2 at 0, 14 and 21 d, respectively), each in triplicate, for HCC827 cell with or without erlotinib. The same t 0 measurements were used for both conditions. A linear mixed model regression was used to quantify differential timecourse trends between treatment conditions. A model with nested (replicate within hairpin) random effects structure was fit for each gene. A random-slope replicate-level random effect and a joint random intercept and slope hairpin-level random npg effect were specified. The fixed-effect portion of the model consisted of three parameters: the common initial measurement (β 0 ), the proliferation trend in untreated HCC827 (β 1 ), and the trend difference associated with erlotinib treatment (β E ). The t statistic estimated for β E was used to determine P values using a t test, with degrees of freedom calculated using the 'between-within' rule 46 . P values were subjected to false discovery rate (FDR) correction using the approach of Benjamini and Hochberg 47 .
At the gene level, the magnitudes of β 1 and β E are correlated, with larger decreases in proliferation in untreated cells (β 1 ) associated with larger magnitude differences between conditions (β E ). In other words, genes that are more essential in general tend to be associated with larger differences between conditions. An alternative measure of synthetic lethality considers the magnitude of the difference (β E ) relative to the magnitude of the baseline trend (β 1 ), thus estimating relative dependence of cell proliferation on a specified gene. We thus use an alternative measure of effect size to rank significant predictions, called the 'relative dropout rate' , defined as 
+ + +
The computation of mixed model variance parameter estimates by maximum likelihood may be problematic when the number of random effect groups is small, for example when three to five hairpins target a gene. In such cases estimates of variance parameters are frequently zero, and estimates of covariance matrices are often singular. Such estimates may artificially inflate significance assigned to model predictions. Boundary avoiding Bayesian priors can mitigate this issue by imposing a weakly informative prior on mixed model variance component estimates 48 . A Wishart prior is applied to the hairpin-level random intercept and slope covariance matrix, and a gamma prior is used for the replicatelevel random slope variance, with each distribution using the default specified parameters 49 . Models were fitted using the R blme package. Replicate measurements obtained from pooled shRNA screens are heteroscedastic, with replicate variance increasing both as mean measurement intensity decreases, and as measurement time-point (number of cell line doublings) increases. However, the small number of replicates makes reliable estimation of replicate variance difficult. Similarly to ref. 49 , we assumed a pooled variance estimate, with measurements taken at the same timepoint, and with similar mean intensity, assumed to have similar variance. This smoothed variance estimate is estimated using local regression, and used to assign an inverse-variance (or dispersion) weight to each measurement modeled in the regression.
A detailed description of the method and accompanying R software package are available on request.
